Derivatives of 3,3-diphenylpropylamines

Details Derivatives of 3,3-diphenylpropylamines Derivatives of 3,3-diphenylpropylamines

2011-07-26

2011-07-26

Jarrell, Noble (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S529000, C514S648000, C560S008000, C560S103000, C560S104000, C560S105000, C564S305000

Reexamination Certificate

active

07985772

ABSTRACT:
The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

REFERENCES:
patent: 2556636 (1951-06-01), Sperber at al
patent: 2567245 (1951-09-01), Sperber et al.
patent: 2676964 (1954-04-01), Sperber et al.
patent: 3261841 (1966-07-01), Zenitz
patent: 3446901 (1969-05-01), Macclesfield
patent: 4988730 (1991-01-01), Korbonits et al.
patent: 5382600 (1995-01-01), Jonsson et al.
patent: 5559269 (1996-09-01), Johansson et al.
patent: 5686464 (1997-11-01), Johansson et al.
patent: 5922914 (1999-07-01), Gage et al.
patent: 6310248 (2001-10-01), Andersson et al.
patent: 6313132 (2001-11-01), Johansson et al.
patent: 6517864 (2003-02-01), Orup Jacobsen et al.
patent: 6566537 (2003-05-01), Andersson et al.
patent: 6630162 (2003-10-01), Nilvebrant et al.
patent: 6689916 (2004-02-01), Andersson et al.
patent: 6713464 (2004-03-01), Meese et al.
patent: 6770295 (2004-08-01), Kreilgard et al.
patent: 6783769 (2004-08-01), Arth et al.
patent: 6809214 (2004-10-01), Meese
patent: 6809225 (2004-10-01), Donsbach et al.
patent: 6858650 (2005-02-01), Meese
patent: 6890920 (2005-05-01), Richards et al.
patent: 6911217 (2005-06-01), Gren et al.
patent: 7008637 (2006-03-01), Jacobsen et al.
patent: 7230030 (2007-06-01), Meese et al.
patent: 7384980 (2008-06-01), Meese et al.
patent: 2003/0152624 (2003-08-01), Aldrich et al.
patent: 2004/0064821 (2004-04-01), Rousselle
patent: 2005/0004223 (2005-01-01), Slatter et al.
patent: 2006/0014832 (2006-01-01), Breitenbach et al.
patent: 2009/0012159 (2009-01-01), Breitenbach et al.
patent: 2009/0042981 (2009-02-01), Meese et al.
patent: 2009/0274761 (2009-11-01), Breitenbach et al.
patent: 830193 (1952-02-01), None
patent: 766207 (1952-12-01), None
patent: 925468 (1955-03-01), None
patent: 1216318 (1966-05-01), None
patent: 325571 (1989-07-01), None
patent: 667852 (1995-08-01), None
patent: 831799 (1996-06-01), None
patent: 872233 (1997-04-01), None
patent: 948321 (1997-12-01), None
patent: 957073 (1998-05-01), None
patent: 1019358 (2000-07-01), None
patent: 1077912 (2001-02-01), None
patent: 1128819 (2001-09-01), None
patent: 624117 (1949-05-01), None
patent: 627139 (1949-07-01), None
patent: 685696 (1953-01-01), None
patent: 689835 (1953-04-01), None
patent: 690274 (1953-04-01), None
patent: 692931 (1953-06-01), None
patent: 1025041 (1964-02-01), None
patent: 1169944 (1969-11-01), None
patent: 1169945 (1969-11-01), None
patent: 89/06644 (1989-07-01), None
patent: 93/23025 (1993-11-01), None
patent: 94/11337 (1994-05-01), None
patent: 96/12477 (1996-05-01), None
patent: 98/03067 (1998-01-01), None
patent: 98/43942 (1998-10-01), None
patent: 98/56359 (1998-12-01), None
patent: 99/58478 (1999-11-01), None
patent: 00/12069 (2000-03-01), None
patent: 00/27364 (2000-05-01), None
patent: 01/34139 (2001-05-01), None
patent: 02/11702 (2002-02-01), None
patent: 02/089773 (2002-11-01), None
patent: 03/002059 (2003-01-01), None
patent: 03/007918 (2003-01-01), None
patent: 03/020241 (2003-03-01), None
patent: 03/021271 (2003-03-01), None
patent: 03/026564 (2003-04-01), None
patent: 03/035599 (2003-05-01), None
patent: 03/039464 (2003-05-01), None
patent: 03/063834 (2003-08-01), None
patent: 03/099268 (2003-12-01), None
patent: 03/103637 (2003-12-01), None
patent: 03/106421 (2003-12-01), None
patent: 2004/019892 (2004-03-01), None
Nilvebrant, “The mechanism of action of tolterodine,” 2000, Reviews in Contemporary Pharmacotherapy 11;13-27.
Nilvebrant et al., European Journal of Pharmacology, 327 (1997) pp. 195-207.
Nilvebrant et al., “Antimuscarinic Potency and Bladder Selectivity of PNU-200577, a Major Metabolite of Tolterodine.” Pharmacology and Toxicology, vol. 81, pp. 169-172, 1997.
Nilvebrant et al., “Tolterodine—a New Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data.” Life Sciences, vol. 60 (13/14), pp. 1129-1136, 1997.
Olsson et al., “Food increases the bioavailability of tolterodine but not effective exposure,” 2001, J. Clin. Pharmacol. 41:298-304.
Olsson & Szamosi, “Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder,” 2001, Clinical Pharmacokinetics 40:135-143.
Olsson & Szamosi, “Multiple dose pharmacokinetics of a new once daily extended release formulation versus immediate release tolterodine,” 2001, Clinical Pharmacokinetics 40:227-235.
Paladino et al., “177. Enantioselective Synthesis of (2S)-2-Amino-3-(4-hydroxy-3-phosphonophenyl)propionic Acid (=3′-Phosphono-L-tyrosine) and its Incorporation into Peptides.” Helv. Chim. Acta 76: 2465-2472, 1993.
Pharmacology/Toxicology Review from Application No. 21-518, Center for Drug Evaluation and Research, pp. 1-3, 2004.
Postlind et al., “Tolterodine, a New Muscarinic Receptor Antagonist, is Metabolized by Cytochromes P450 and 3A in Human Liver Microsomes.” Drug Metabolism and Disposition, vol. 26 (4), p. 289-293, 1998.
Rentzhog et al., “Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study,” 1998, Br. J. Urol. 81:42-48.
Roy, et al., “HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine” Circulation vol. 94, No. 4, pp. 817-823, Aug. 15, 1996.
Saa et al., “Metalation of Phenols. Synthesis of Benzoquinones by the Oxidative Degradation Approach.” J. Org. Chem. 53: 4263-4273, 1988.
Sachse et al., “Pharmacodynamics of multiple dose treatment with the novel antimuscarinic drug fesoterodine,” 2002, Nauyn-Schmiedeberg's Arch. Pharmacol. 365 (Suppl. 1):413.
Sachse et al., “Safety and pharmacokinetics of the novel bladder-selective antimuscarinic drug fesoterodine in populations of different age or gender,” 2002, Proceedings of the International Continence Society, 32:441.
Sachse et al., “Safety and pharmacokinetics of the novel bladder-selective antimuscarinic fesoterodine in populations of different ethnic origin,” 2003, Proceedings of the International Continence Society, 33:377.
Sachse et al., “Dose-proportional pharmacokinetics of the new antimuscarinic fesoterodine,” 2003, Nauyn-Schmiedeberg's Arch. Pharmacol. 367 (Suppl. 1):446.
Sachse et al., “Pharmacodynamics and pharmacokinetics of ascending multiple oral doses of the novel, bladder-selective antimuscarinic fesoterodine,” 2003, Eur. Urol. Suppl 2:111.
Sachse et al., “Concomitant food intake does not significantly influence the pharmacokinetics of the novel, bladder-selective antimuscarinic fesoterodine,” 2004, Proceedings of the International Continence Society, 34:580.
Sachse et al., “Safety, tolerability and pharmacokinetics of fesoterodine in patients with hepatic impairment,” 2004, Proceedings of the International Continence Society, 34:585.
Sachse et al., “Safety, tolerability and pharmacokinetics of fesoterodine after co-treatment with the potent cytochrome P450 3A4 inhibitor ketoconazole,” 2004, Proceedings of the International Continence Society, 34:586.
Sachse et al., “Clinical pharmacological aspects of the novel bladder-selective antimuscarinic fesoterodine,” 2004, Progrès en Urologie, 14 (Suppl. 3):58.
Stahl et al., “Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor ove

Affiliated with

Also associated with

Rating

Derivatives of 3,3-diphenylpropylamines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of 3,3-diphenylpropylamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of 3,3-diphenylpropylamines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2639032